Earlier this morning AroCell communicated the positive news that the company has submitted its FDA filing for TK210 ELISA. Previously, we expected the filing to take place in H1 2021 and view the filing as an important catalyst, further demonstrating AroCell to be on track with the coming commercialization of its immunoassay.